Aug 8, 2018 | Featured Insights
Last week, Dallas-based Baron & Budd secured a major settlement with Endo Pharmaceuticals Inc. (“Endo”), which agreed to pay $13.25 million for fraudulently marketing Lidoderm for unapproved use. This, the suit claimed, was an alleged violation of federal and...